Doseology SciencesDOSEF -16.16%33 Days Payable is 55.23 as of Mar. 2026, which is 90% below its 10-year median of 575.81. GuruFocus rates DOSEF with a GF Score™ of 33/100 and a GF Value™ of $0.17 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 706 Biotechnology companies, Doseology Sciences ranks better than 56.94% on this metric.
The historical rank and industry rank for Doseology Sciences's Days Payable or its related term are showing as below:
DOSEF'
s Days Payable Range Over the Past 10 Years
Min: 149.59 Med: 575.81 Max: 10220
Current: 149.59
During the past 6 years, Doseology Sciences's highest Days Payable was 10220.00. The lowest was 149.59. And the median was 575.81.
DOSEF's Days Payable is ranked better than 56.94% of 706
companies
in the Biotechnology industry
Industry Median: 113.56
vs DOSEF: 149.59
Doseology Sciences's Days Payable
declined
from Mar. 2025 (70.97) to Mar. 2026 (55.23).
It may suggest that Doseology Sciencesaccelerated paying its suppliers.
Doseology Sciences Days Payable Related Terms
Doseology Sciences Days Payable Historical Data
* Premium members only.
The historical data trend for Doseology Sciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DOSEF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Doseology Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Doseology Sciences Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Doseology Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Doseology Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Doseology Sciences's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Doseology Sciences (DOSEF) has a Days Payable of 55.23 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Doseology Sciences and its competitors. This is 90% below median its historical median of 575.81. Over the past decade, Doseology Sciences' Days Payable has ranged from 149.59 to 10,220.00. According to the industry distribution chart, Doseology Sciences ranks #304 out of 706 companies in the Biotechnology industry, placing it in the top 43.1%.
Is Doseology Sciences' Days Payable too high?
Doseology Sciences' current Days Payable of 55.23 is 90% below median its 10-year median of 575.81. Over the past 10 years, this metric has ranged from a low of 149.59 to a high of 10,220.00. The Biotechnology industry median Days Payable is 113.56. Doseology Sciences' value of 55.23 is 51.4% below this industry median. Based on the distribution chart, Doseology Sciences ranks #304 out of 706 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Doseology Sciences has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Doseology Sciences' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Doseology Sciences ranks #304 out of 706 companies for Days Payable. This puts Doseology Sciences in the upper half of its industry. The industry median Days Payable is 113.56. Doseology Sciences' value of 55.23 is 51.4% below this benchmark. Historically, Doseology Sciences' own Days Payable has ranged from 149.59 to 10,220.00 over the past decade. While the company's 10-year median is 575.81 vs. the industry median of 113.56, Doseology Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Doseology Sciences's current Days Payable of 55.23 is 51.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Doseology Sciences and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Doseology Sciences's current Days Payable is 55.23, which is 90% below median its own 10-year median of 575.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Doseology Sciences stock overvalued right now?
Based on GuruFocus' analysis, Doseology Sciences (DOSEF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.17, compared to a current price of $0.11 — trading 34.1% below its estimated fair value. The current Days Payable is 55.23, which is 90% below median its 10-year median of 575.81 and 51.4% below the Biotechnology industry median of 113.56. Doseology Sciences' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Doseology Sciences (DOSEF), the current Days Payable is 55.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Doseology Sciences (DOSEF) Overvalued in 2026?
Based on GuruFocus' analysis, Doseology Sciences stock appears to be undervalued.
The current stock price of $0.11 is trading 34.1% below its estimated GF Value™ of $0.17.
GuruFocus considers Doseology Sciences to be Possible Value Trap.
Key valuation signals for DOSEF:
Days Payable: 55.23 (90% below median its 10-year median of 575.81)
GF Value™: $0.17 vs. price of $0.11 (34.1% below fair value)
Industry Position: 51.4% below the Biotechnology median (#304 of 706)
No single metric tells the full story. See the DOSEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Doseology Sciences Inc is a diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on the psychedelic and non-psychedelic compounds, also sale of its branded functional mushroom products. It offers cutting-edge therapeutic products and services, with the focus of making a meaningful impact on the mental health pandemic and improving overall health. Geographically earns it revenue from Canada.
33GF Score
Get the complete analysis for DOSEF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DOSEF has been successfully added to your 
